Synthesis and immunological activity of water-soluble thalidomide prodrugs

Bioorganic and Medicinal Chemistry

Volumn 9, Issue 5, 2001, Pages 1279-1291

  Hess, Sonja ^a   Akermann, Michaela A ^a   Wnendt, Stephan ^b   Zwingenberger, Kai ^c   Eger, Kurt ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Grünenthal   (Germany)

^c Medical Scientific Division   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLE 2 YL) 2,6 DIOXOPIPERIDINE 1YLMETHYL] 1,4 DIHYDROPYRIDINE 3 CARBOXYLIC ACID AMIDE; 2 (1 HYDROXYMETHYL 2,6 DIOXOPIPERIDINE 3 YL) 1,3 DIHYDRO 2H ISOINDOLE 1,3 DIONE; 2 (1 METHOXYMETHYL 2,6 DIOXOPIPERIDINE 3 YL) 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLE 1,3 DIONE; 2 (AMINOACETYLAMINO)ACETIC ACID [3 (1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLE 2 YL) 2,6 DIOXOPIPERIDINE 1 YLMETHYL]ESTER; 2 [(1 AZIDOMETHYL) 2,6 DIOXOPIPERIDINE 3 YL] 1,3 DIIHYDRO 2H ISOINDOLE 1,3 DIONE; 2 [3 (4 HYDROXYPHENYL)PROPIONYLAMINO] 3 METHYLBUTYRIC ACID [3 (1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLE 2 YL) 2,6 DIOXOPIPERIDINE 1 YLMETHYL]ESTER; 2 AMINO 3 METHYLBUTYRIC ACID [3 (1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLE 2 YL) 2,6 DIOXOPIPERIDINE 1 YLMETHYL]ESTER; 2 AMINOACETIC ACID [3 (1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLE 2 YL) 2,6 DIOXOPIPERIDINE 1 YLMETHYL]ESTER; 2 METHYLAMINO(PROPIONIC ACID) [3 (1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLE 2 YL) 2,6 DIOXOPIPERIDINE 1 YLMETHYL]ESTER; 3 CARBAMOYL 1 [3 (1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLINE 2 YL) 2,6 DIOXOPIPERIDINE 1 YLMETHYL]PYRIDINIUM CHLORIDE; 3 CARBOXY 1 [3 (1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLINE 2 YL) 2,6 DIOXOPIPERIDINE 1 YLMETHYL]PYRIDINIUM IODIDE; [3 (1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLE 2 YL) 2,6 DIOXOPIPERIDINE 1 YL]ACETIC ACID; N TERT BUTYLOXYCARBONYL 2 AMINOACETIC ACID [3 (1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLE 2 YL) 2,6 DIOXOPIPERIDINE 1 YLMETHYL]ESTER; PRODRUG; SUCCINIC ACID MONO[3 (1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOLE 2 YL) 2,6 DIOXOPIPERIDINE 1 YLMETHYL]ESTER; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DERIVATIZATION; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PHARMACOPHORE; REACTION ANALYSIS; SHWARTZMAN PHENOMENON;

ANIMALS; BINDING SITES; DRUG STABILITY; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; INTERLEUKIN-2; KINETICS; MALE; MICE; PERMEABILITY; SHWARTZMAN PHENOMENON; SOLUBILITY; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; WATER;

EID: 0035008826     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(00)00342-4     Document Type: Article

References (41)

1. Lenz W. Dt. Med. Wochenschr. 86:1961;2555.
2. Lenz W. Lancet. 1:1962;271.
3. Lenz W. Teratology. 38:1988;203.
4. Ehninger G., Eger K., Stuhler A., Schuler U. Bone Marrow Transplant. 12(Suppl.):1993;26.
5. Hashimoto Y. Curr. Med. Chem. 5:1998;163.
6. Calabrese L., Fleischer A.B. Jr. Am. J. Med. 108:2000;487.
7. Tseng S., Pak G., Washenik K., Pomeranz M.K. J. Am. Acad. Dermatol. 35:1996;969.
8. Spilker B., FritzSimmons S., Horan M. Drug Develop. Res. 48:1999;139.
9. Koch H.P., Steinacker C. Arch. Pharm. Pharm. Med. Chem. 321:1988;371.
10. Krenn M., Gamcsik M.P., Vogelsang G.B., Colvin O.M., Leong K.W. J. Pharm. Sci. 81:1992;685.
11. Sauer H., Guenther J., Hescheler J., Wartenberg M. Am. J. Pathol. 156:2000;151.
12. Thiel R., Kastner U., Neubert R. Life Science. 66:2000;133.
13. Thiele A., Thormann M., Hofmann H.-J., Naumann W.W., Eger K., Hauschildt S. Life Science. 67:2000;457.
14. Stephens T.D., Fillmore B.J. Teratology. 61:2000;189.
15. Wermuth, C. G., Gaignault, J.-C., Marchandeau, C. In The Practice of Medicinal Chemistry; Wermuth, C. G., ed.; Academic: London, 1996, 671-696.
16. Williams A., Ibrahim I.T. Chem. Rev. 81:1981;589.
17. Pop E., Liu Z.Z., Brewster E.M., Barenholz Y., Korblyov V., Mechoulam R., Nadler V., Biegon A. Pharm. Res. 13:1996;62.
18. Rautio J., Nevalainen T., Taipale H., Vepsäläinen J., Gynther J., Laine K., Järvinen T. J. Med. Chem. 43:2000;1489.
19. Hassner A., Alexanian V. Tetrahedron Lett. 46:1978;4475.
20. Cho M.J., Haynes L.C. J. Pharm. Sci. 74:1985;883.
21. Sieber P., Iselin B. Helv. Chim. Acta. 51:1968;522.
22. Ragnarsson U., Karlsson S., Lindeberg G. Acta Chem. Scand. 24:1970;2821.
23. Rudinger J., Ruegg U. Biochem. J. 133:1973;538.
24. Bolton A.E., Hunter W.M. Biochem. J. 133:1973;529.
25. Bodor N., Farrag H.H. J. Med. Chem. 26:1983;313.
26. Pop E., Shek E., Murakami T., Bodor N.S. J. Pharm. Sci. 78:1989;609.
27. Phelan M.J., Bodor N. Pharm. Res. 6:1989;667.
28. Gal J. J. Pharm. Sci. 68:1979;1562.
29. Broto P., Moreau G., Vandyke C. Eur. J. Med. Chem. - Chim Ther. 19:1984;71.
30. ChemDraw Ultra Version 5.0; Cambridge Soft Corporation: Cambridge, MA, USA, 1999.
31. Buchwald P., Bodor N. Curr. Med. Chem. 5:1998;353.
32. Trapani G., Latrofa A., Franco A., Lopedota A., Maciocco E., Liso G. Int. J. Pharm. 175:1998;195.
33. Beauchamp L.M., Krenitsky T.A. Drugs Fut. 18:1993;619.
34. Payne J.W. Drugs Exp. Clin. Res. 12:1986;585.
35. Ames B.N., Ames G.G.-L., Young J.D., Tsuchiya D., Lecocq J. Proc. Natl. Acad. Sci. U.S.A. 70:1973;456.
36. Schumacher H., Smith R.L., Williams R.T. Br. J. Pharmacol. 25:1965;324.
37. Teubert U., Zwingenberger K., Wnendt S., Eger K. Arch. Pharm. Pharm. Med. Chem. 331:1998;7.
38. Zimmer, O.; Winter, W.; Wnendt, S.; Zwingenberger, K.; Eger, K.; Teubert U., EP 856,513, August 15 1998.
39. Geist C., Woehrmann T., Schneider J., Zwingenberger K. FEMS Immunol. Med. Microbiol. 12:1995;165.
40. Muller G.W., Shire M.G., Wong L.M., Corral L.G., Patterson R.T., Chen Y., Stirling D.I. Bioorg. Med. Chem. Lett. 8:1998;2669.
41. Schumacher H., Smith R.L., Williams R.T. Br. J. Pharmacol. 25:1965;338.